United Therapeutics Corporation (UTHR)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases in the United States and international markets. Its commercial portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and the Remunity Pump system. The company is also advancing additional programs for pulmonary arterial hypertension, including RemunityPRO Pump and Ralinepag, as well as Nebulized Tyvaso for idiopathic pulmonary fibrosis. Beyond its marketed products and pipeline, United Therapeutics is pursuing xenograft and regenerative medicine initiatives, including preclinical organ and tissue development programs. The company has collaboration and licensing arrangements with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, and was founded in 1996. It is headquartered in Silver Spring, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-UTHR
|
$489.64
|
-7.9% Downside
|
Fair
|
$663.46
|
24.8% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
17.5x
|
3.8x
|
7.1x
|
22.469 B
|
19.072 B
|
0.0%
|
91.7%
|
20.1
|
—
|
79.0%
|
